


## Empower Your Drug-Discovery AI to Tackle Any Compound, Any Workflow



## Advantages

- 01. Can transfer the capabilities learned from massive amounts of data to Individual AI models (Confirmed 10-30% rise in performance)
- 02. Can reduce the time required for training individual AI models by 10-100 fold
- 03. The Foundation AI is our own, but Individual AIs trained based on it can be sold/licensed separately

## Performance

	Our Model Using SG4D1B	Competitor 1*2	Competitor 2*3
Accuracy*1	0.8942	0.7288	0.4750

- \*1 Using PRAUC for a group of compounds randomly selected from the Enamine Real Database.
- Calculate the average value for 9 initial toxicity/pharmacokinetic parameters
  \*2 Using HealixADMET. https://academic.oup.com/bioinformatics/article/38/13/3444/6590643
- \*3 Using admetSAR 2.0. https://academic.oup.com/bioinformatics/article/35/6/1067/5085368

## Achievements

- Presented at NVIDIA's Annual GTC Conference
- Discovered novel strong Inhibitors to certain clinical targets
- Discovered novel double-inhibitor for a clinical target
- Discovered novel Inhibitors with satisfactory ADME-Tox
- Discovered novel structures for a pesticide target
- Discovered 4 novel PET-degrading Enzymes
- Discovered a novel plastic-degrading enzyme with just one training data point
- Discovered novel Methane-producing enzymes